Aarti Pharmalabs Limited - Asset Resilience Ratio

Latest as of March 2025: 1.69%

Aarti Pharmalabs Limited (AARTIPHARM) has an Asset Resilience Ratio of 1.69% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AARTIPHARM current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs491.23 Million
≈ $5.31 Million USD Cash + Short-term Investments

Total Assets

Rs29.06 Billion
≈ $314.32 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how Aarti Pharmalabs Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AARTIPHARM total asset value.

Liquid Assets Composition Over Time

This chart breaks down Aarti Pharmalabs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Aarti Pharmalabs Limited carry for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs491.23 Million 1.69%
Total Liquid Assets Rs491.23 Million 1.69%

Asset Resilience Insights

  • Limited Liquidity: Aarti Pharmalabs Limited maintains only 1.69% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Aarti Pharmalabs Limited Industry Peers by Asset Resilience Ratio

Compare Aarti Pharmalabs Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
Drug Manufacturers - Specialty & Generic 0.35%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 0.50%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
Drug Manufacturers - Specialty & Generic 0.46%
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
Drug Manufacturers - Specialty & Generic 0.00%
Teyi Pharmaceutical Group Co Ltd
SHE:002728
Drug Manufacturers - Specialty & Generic 9.66%

Annual Asset Resilience Ratio for Aarti Pharmalabs Limited (2023–2025)

The table below shows the annual Asset Resilience Ratio data for Aarti Pharmalabs Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 1.69% Rs491.23 Million
≈ $5.31 Million
Rs29.06 Billion
≈ $314.32 Million
-1.04pp
2024-03-31 2.73% Rs703.98 Million
≈ $7.61 Million
Rs25.82 Billion
≈ $279.24 Million
+0.45pp
2023-03-31 2.27% Rs509.90 Million
≈ $5.51 Million
Rs22.44 Billion
≈ $242.68 Million
--
pp = percentage points

About Aarti Pharmalabs Limited

NSE:AARTIPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$797.00 Million
Rs73.70 Billion INR
Market Cap Rank
#9951 Global
#490 in India
Share Price
Rs813.00
Change (1 day)
+2.98%
52-Week Range
Rs591.95 - Rs930.20
All Time High
Rs964.90
About

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more